SaadZafarUsmaniMDMBA FACP FRCP FASCO(He/Him)

Hematologic Oncology, Clinical Pharmacology

Professor of Medicine

Overview of Dr. Usmani

Dr. Saad Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He is an internationally known clinical and translational researcher in multiple myeloma and associated plasma cell disorders.

Office
225 Summit Avenue
Montvale, NJ 07645
Book by Phone+1(205) 267-5426

Education & Training

Kenan-Flagler Business School, University of North CarolinaMBA, Concentration in Strategy, Leadership and Entrepreneurship , 2019 - 2020
University of ConnecticutFellowship, Hematology and Medical Oncology, 2007 - 2010
Wayne State University School of MedicineResidency, Internal Medicine, 2004 - 2007
Allama Iqbal Medical CollegeClass of 2002

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2021 - 2026
CT State Medical License 2012 - 2025
NC State Medical License 2013 - 2025
NJ State Medical License 2013 - 2025
SC State Medical License 2022 - 2025
MI State Medical License 2004 - 2019
TX State Medical License 2013 - 2016
AR State Medical License 2010 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology
Join now to see all

Clinical Trials

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Start of enrollment: 2008 Jul 01
Active, not recruiting
Phase 3
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma Start of enrollment: 2011 Oct 01
Completed
Phase 2
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma Start of enrollment: 2012 Jun 26
Active, not recruiting
Phase 1, Phase 2
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis Start of enrollment: 2012 Dec 26
Terminated
Phase 3
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma Start of enrollment: 2012 Nov 01
Active, not recruiting
Phase 1, Phase 2
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2013 Dec 01
Completed
Phase 1, Phase 2
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD Start of enrollment: 2013 Sep 27
Completed
Phase 2
A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma Start of enrollment: 2013 Nov 01
Completed
Phase 2
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma Start of enrollment: 2014 Feb 18
Completed
Phase 1
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Jul 30
Terminated
Phase 1
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Start of enrollment: 2014 May 23
Active, not recruiting
Phase 3
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) Start of enrollment: 2014 May 01
Completed
Phase 2
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma Start of enrollment: 2015 Feb 16
Active, not recruiting
Phase 3
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma Start of enrollment: 2014 Dec 11
Completed
Phase 2
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients Start of enrollment: 2015 May 15
Completed
Phase 1
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis Start of enrollment: 2015 Feb 01
Terminated
Phase 3
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM Start of enrollment: 2015 May 07
Active, not recruiting
Phase 2
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2015 Oct 22
Completed
Phase 1
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma Start of enrollment: 2015 Sep 01
Active, not recruiting
Phase 3
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) Start of enrollment: 2015 Oct 19
Terminated
Phase 3
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) Start of enrollment: 2015 Oct 19
Terminated
Phase 3
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. Start of enrollment: 2016 Feb 09
Completed
Phase 2
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2016 Jan 11
Active, not recruiting
Phase 1
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Start of enrollment: 2016 Apr 25
Completed
Phase 1, Phase 2
PRospective Multiple Myeloma Impact Study Start of enrollment: 2018 Feb 27
Active, not recruiting
Not Applicable
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma Start of enrollment: 2017 Jan 17
Completed
Phase 1
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2017 May 16
Recruiting
Phase 1
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Start of enrollment: 2017 Jun 13
Completed
Phase 3
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2019 Jul 17
Active, not recruiting
Phase 2
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2018 Jan 09
Active, not recruiting
Phase 2
A Safety Study of SGN-CD48A in Patients With Multiple Myeloma Start of enrollment: 2018 Feb 20
Terminated
Phase 1
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2018 Jun 29
Completed
Phase 1, Phase 2
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Start of enrollment: 2018 Dec 13
Recruiting
Phase 2
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Start of enrollment: 2019 Apr 16
Active, not recruiting
Phase 3
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma Start of enrollment: 2019 Jan 03
Completed
Phase 1, Phase 2
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma Start of enrollment: 2019 Dec 18
Recruiting
Phase 1
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Start of enrollment: 2020 Jan 10
Active, not recruiting
Phase 2
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma Start of enrollment: 2021 Jul 02
Withdrawn
Phase 2
Study of Dara-Pembro for Multiple Myeloma Patients Start of enrollment: 2021 Jun 09
Withdrawn
Phase 2
COVID19 OutcomeS in Myeloma and the Impact of VaCcines Start of enrollment: 2024 Jan 23
Active, not recruiting
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma Start of enrollment: 2022 Jun 20
Recruiting
Phase 1
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2022 Oct 18
Recruiting
Phase 1, Phase 2
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2021 Oct 05
Active, not recruiting
Phase 1
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients Start of enrollment: 2022 Mar 07
Recruiting
Phase 2
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy Start of enrollment: 2023 Sep 27
Recruiting
Phase 2
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2023 Feb 22
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Diana Cortes-Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein
Blood. 2024-08-08
446 citations
IMWG consensus on risk stratification in multiple myeloma
Wee Joo Chng, Angela Dispenzieri, C. S. Chim, R Fonseca, H. Goldschmidt
Leukemia. 2014-02-01
2788 citations
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar, Meletios A. Dimopoulos, Antonio Palumbo, Joan Bladé, Giampaolo Merlini
The Lancet. Oncology. 2014-11-01

Journal Articles

Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-Risk Cytogenetic Factors
Susan Bal, Benjamin Djulbegovic, Saad Z Usmani, JAMA Oncology

Abstracts/Posters

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Tra...
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refr...
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: ...
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagno...
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible f...
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed ...
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
Saad Z. Usmani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refr...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Friday Scientific Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Current Obstacles in Myeloma Management: Debating the Evidence
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagno...
2019 ASCO Annual Meeting - 6/1/2019
Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) – Effectiveness in Routine Clinical Practice Is Similar to t...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Ope...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Anal...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Approach to the Treatment of the Young, Fit Patient With Myeloma: From Diagnosis to Relapse
60th American Society of Hematology Annual Meeting - 12/1/2018
Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical TrialsClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
De-Escalation of Antimicrobials in Adult Hematopoietic Cell Transplantation Recipients with Febrile Neutropenia of Unknown Origin
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refr...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

‘Exciting’ Research Spotlights CAR-t’s Evolving Role in Blood Cancer TreatmentFebruary 22nd, 2023
Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
What's on Tap at the Society of Hematologic Oncology's 10th Annual MeetingSeptember 26th, 2022
Join now to see all

Grant Support

Optimizing Risk and Response Adaptive Strategies Using Immunotherapy in Multiple MyelomaLeukemia Lymphoma Society2017–2022
PET SCAN FOR PROGNOSTICATION IN NEWLY DIAGNOSED HIGH RISK MULTIPLE MYELOMANCI2015–2021

Professional Memberships

American College of Physicians - ACP
Fellow
American Association for Cancer Research - AACR
Member
American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member

Other Languages

Hindi, Urdu, Punjabi

External Links

Company websitehttps://www.mskcc.org/cancer-care/doctors/saad-usmani

Insurance Accepted

Aetna Choice POS II
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Qualchoice PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment